Table 3

Distribution of DNO in the intervention and control groups

Intervention group, N (%)
(n=59)
Control group, N (%)
(n=59)
p Value*
Drug-related negative outcomes
Poor glycaemic control23 (39.0)24 (40.7)0.849
Poor blood pressure control6 (10.2)19 (32.2)0.003
Poor control of serum potassium6 (10.2)8 (13.6)0.569
Poor coagulation control5 (8.5)14 (23.7)0.024
Plasma digoxin outside the normal range3 (5.1)3 (5.1)1
Pain4 (6.8)3 (5.1)0.697
Nephrotoxicity1 (1,7)3 (5.1)0.309
Poor heart rate control2 (3.4)3 (5.1)0.648
Headache1 (1.7)-0.315
Somnolence1 (1.7)-0.315
Metabolic alkalosis1 (1.7)-0.315
Vomiting1 (1.7)0.315
Cognitive decline-1 (1.7)0.315
Diarrhoea-1 (1.7)0.315
Acute urinary retention-1 (1.7)0.315
Constipation-1 (1.7)0.315
ATC Group of the drug involved in DNO
A (Alimentary tract and metabolism)25 (42.4)27 (45.8)0.711
B (Blood and blood-forming organs)5 (8.5)13 (22.0)0.041
C (Cardiovascular system)14 (23.7)27 (45.8)0.012
G (Genitourinary system and sex hormones)-2 (3.4)0.154
J (Anti-infective agents for systemic use)1 (1.7)1 (1.7)1
M (Musculoskeletal system)2 (3.4)2 (3.4)1
N (Nervous system)3 (5.1)3 (5.1)1
R (Respiratory system)1 (1.7)-0.315
  • (-) refers to variables in which no cases were found.

  • *p refers to results from chi-squared test.

  • † Statistically significant differences (p<0.05).

  • DNO, Drug-related negative outcomes.